Ypsomed Holding AG engages in the development and manufacture of injection systems for self-medication of drugs by patients, most notably used to treat diabetes. Its products include DiaExpert, BGMS, OmniPod, YpsoPump & Orbit, Pen needles, Injection systems, and Contract manufacturing. The company operates through the following business segments: Diabetes Direct Business, Delivery Devices, Products, Ypsomed Diabetes Care, Ypsomed Delivery Systems. The Delivery Devices segment consists of business with the product group's pen systems, pen needles, infusion sets and other injection molded parts that are developed and manufactured by company. The Diabetes Direct Business segment consists of the sales and direct trade business with various supplies for diabetes care, for example, devices for the self-monitoring of blood glucose levels as well as infusion pumps, accessories and other day-to-day items for diabetics. The Ypsomed Diabetes Care segment owns, manufactures and trade products are marketed under the brand mylife Diabetescare directly to hospitals, physicians, pharmacies and patients via Ypsomed's subsidiaries and distributors. The Ypsomed Delivery Systems segment concerns B2B business and is directly managed by the company. Ypsomed Holding was founded by Wilhelm Michel on December 29, 2003 and is headquartered in Burgdorf, Switzerland.